Aclaris Therapeutics今日宣布,其创新药物ATI-052——一款靶向TSLP/IL-4Rα的双特异性抗体,在1a期临床试验中取得了积极的中期结果。这一关键进展为后续的加速临床开发计划提供了有力支持。
Aclaris Therapeutics今日宣布,其创新药物ATI-052——一款靶向TSLP/IL-4Rα的双特异性抗体,在1a期临床试验中取得了积极的中期结果。这一关键进展为后续的加速临床开发计划提供了有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.